June 17, 2020

US Bioservices now dispenses XOSPATA® (gilteritinib)

XOSPATA® is an oral once-daily kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.